Mylan NV (MYL)

20.12 -0.19  -0.94% NASDAQ Feb 25, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/07/2020 10:00 EDT Misc Mylan NV First Quarter Earnings Conference Call in 2020
05/07/2020 Earnings Mylan NV First Quarter Earnings in 2020 Release
02/27/2020 16:30 EST Misc Mylan NV Fourth Quarter Earnings Conference Call for 2019
02/27/2020 Earnings Mylan NV Fourth Quarter Earnings Results for 2019
11/05/2019 Earnings Mylan NV Third Quarter Earnings in 2019 Release
11/05/2019 10:00 EST Misc Mylan NV Third Quarter Earnings Conference Call for 2019
07/29/2019 08:30 EDT Misc Mylan NV Second Quarter Earnings Conference Call in 2019
07/29/2019 Earnings Mylan NV Second Quarter Earnings in 2019 Release
06/21/2019 12:00 CEST Misc Mylan NV Annual General Meeting in 2018
05/07/2019 10:00 EDT Misc Mylan NV First Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.mylan.com
  • Investor Relations URL: http://investor.mylan.com/index.cfm
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Equity Style: Mid Cap/Value
  • Next Earnings Release: Feb. 27, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Jun. 27, 2007
  • Description: Registered in the Netherlands, Mylan is a leading generic drugmaker, with roughly 55 manufacturing and R&D facilities. Although the company was formed in 1961, the company's position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merk KGaA transaction.

Top Fund Holders

Symbol Name Weighting
XPH SPDR® S&P Pharmaceuticals ETF 4.55%
IHE iShares US Pharmaceuticals ETF 4.23%
VVONX Invesco Value Opportunities R5 2.28%
F000014K2A Invesco Small Cap Value R 2.27%
IGI1123 IG Mackenzie Global Health Care Cl J NL 2.22%
DLRHX Delaware Healthcare R 2.04%
VGHCX Vanguard Health Care Inv 1.90%
FXH First Trust Health Care AlphaDEX® ETF 1.78%
RYH Invesco S&P 500® Equal Wt Hlth Care ETF 1.74%
RPV Invesco S&P 500® Pure Value ETF 1.43%
IBB iShares Nasdaq Biotechnology ETF 1.30%
ATL1635 Renaissance Global Health Care Class F 1.30%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.